Pharmacologic Management of Chronic Urticaria in Pediatric Patients: The Gap Between Guidelines and Practice

Williams, Paul V.

doi:10.1007/s40272-019-00365-3

Cited by 14 publications

(15 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic urticaria is defined by recurrent wheals, with or without angioedema, that persist for six weeks or longer [ 2 ]. The identification rate of a specific cause of chronic urticaria ranges between 15 and 20% [ 9 ] but, similar to acute urticaria, infections, inducible factors (e.g. physical), food and drugs are the most common triggers [ 1 , 4 , 9 ].…”

Section: Classification Of Urticariamentioning

confidence: 99%

“…The identification rate of a specific cause of chronic urticaria ranges between 15 and 20% [ 9 ] but, similar to acute urticaria, infections, inducible factors (e.g. physical), food and drugs are the most common triggers [ 1 , 4 , 9 ].…”

Section: Classification Of Urticariamentioning

confidence: 99%

“…The analysis by age group from the Global Burden of Disease Study showed that children aged 1–9 years old have the highest burden of disease among the pediatric population [ 44 ]. Epidemiological data on urticaria in children are limited but the prevalence of all forms of childhood urticaria is estimated to be around 2–6% [ 9 ]. Chronic urticaria prevalence varies according to studies.…”

Section: Burden Of Diseasementioning

confidence: 99%

See 2 more Smart Citations

Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride

Ansotegui

Bernstein

Canonica

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Objective The present narrative review provides a comprehensive update of the current knowledge on urticaria, both in adult and pediatric populations, and on the safety and efficacy of fexofenadine hydrochloride (HCl) as a treatment option. Data source A literature search was conducted on Embase and Medline. Study selection Clinical studies published in English and published between 1999 and 2020 were selected. Results Although the exact pathogenesis of urticaria is not fully understood, multiple pathways of mast cell activation are discussed to explain the existence of phenotypically different clinical manifestations of urticaria. An overview of the worldwide prevalence of chronic urticaria, including disease burden and patient’s quality of life is provided. The impact of urticaria on patient’s life differs on the basis of whether its form is acute or chronic, but pharmacological approaches are most often needed to control the disabling symptoms. A summary of the current management of urticaria recommended by different guidelines across countries (Global; European; American; Australian; Asian; Japanese) is presented. Non-sedating, second-generation H1-antihistamines are the preferred choice of treatment across several guidelines worldwide. Herein, the efficacy and safety of fexofenadine HCl, a representative second-generation H1-antihistamine approved for the treatment of urticaria, is discussed. The occurrence of urticaria manifestations in COVID-19 patients is also briefly presented. Conclusion The burden of acute and chronic urticaria is high for patients. Second generation anti-histamines such as fexofenadine HCl can help managing the symptoms.

show abstract

Section: Classification Of Urticariamentioning

confidence: 99%

Section: Classification Of Urticariamentioning

confidence: 99%

Section: Burden Of Diseasementioning

confidence: 99%

See 1 more Smart Citation

Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride

Ansotegui

Bernstein

Canonica

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

show abstract

“…Table 2. The recommended doses for some of the second generation antihistamines in infants and children Fexofenadine 9,45 Step 1…”

Section: Discussionmentioning

confidence: 99%

Overview on chronic spontaneous urticaria in the pediatric age groups

Osman

2021

Egypt J Pediatr Allergy Immunol

View full text Add to dashboard Cite

“…antihistamines are the treatment of choice and the addition of corticosteroids may improve control of exacerbation [4]. Novel approaches such as omalizumab, have been found to be highly effective and safe [5].…”

Section: Allergy 1-chronic Urticaria; 2-cow's Milk Allergy; 3-type 1mentioning

confidence: 99%

Best practices, challenges and innovations in pediatrics in 2019

et al. 2020

View full text Add to dashboard Cite

This paper runs through key progresses in epidemiology, pathomechanisms and therapy of various diseases in children that were issued in the Italian Journal of Pediatrics at the end of last year. Novel research and documents that explore areas such as allergy, critical care, endocrinology, gastroenterology, infectious diseases, neonatology, neurology, nutrition, and respiratory tract illnesses in children have been reported. These observations will help to control childhood illnesses.

show abstract

Pharmacologic Management of Chronic Urticaria in Pediatric Patients: The Gap Between Guidelines and Practice

Cited by 14 publications

References 42 publications

Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride

Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride

Overview on chronic spontaneous urticaria in the pediatric age groups

Best practices, challenges and innovations in pediatrics in 2019

Contact Info

Product

Resources

About